FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Despite safety problems, Vioxx still in demand


Free newsletter via e-mail
Tools

Maybe some people still don't know what's bad for them. Patients who once dependent on Vioxx for arthritis relief are still lobbying Merck to get the drug back on the market--despite the documented risk of heart attacks, strokes, even death. Consumer advocates say it might be a case of rose-colored hindsight; patients convinced only Vioxx can help them may simply have exaggerated memories of the drug's effects. But patients say they simply want to make their own choices. Don't smokers say the same thing?

- here's the report from the Star-Ledger

Related Articles:
Vioxx defense dealt a blow by new study results. Report
Up to 100,000 Vioxx claims expected. Report
Merck faces long road in Vioxx battle. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter: